Ron Strider
Well-Known Member
Chicago, IL – November 1, 2017 – Aclara Research, a leader in the development of patient and consumer insights within the cannabis industry, today released the preliminary results of their latest study examining patient usage of medical cannabis and the impact on prescription opioid usage. The study, which was conducted in partnership with a group of pharmacist professionals active within the cannabis industry, found that 67 percent of patients stopped using opioid medications after using medical cannabis. The study further went on to find that 30 percent of patients stopped using prescription drugs completely after using medical cannabis.
The study also examined pharmacist perception of medical cannabis and their role in dispensing and counseling patients. Aclara and the participating pharmacists, partnered with patient advocacy groups, dispensaries and the National Community Pharmacists Association to field online surveys of each audience, resulting in more than 400 patients and 500 pharmacists nationwide.
While the full study will be released in early 2018, key preliminary findings from the research study include:
• Sixty seven percent of patients stopped using opioid medications after using medical cannabis. In addition, 29 percent of patients reported a decrease in the number of opioid medications after starting medical cannabis.
• Thirty percent of study respondents stopped using all prescription drugs after using medical cannabis.
• Eighty seven percent of pharmacists participating in the study said cannabis should be legal for medical usage. Only 15 percent of patients are talking to their pharmacist about medical cannabis. Instead, over 40 percent of patients said they obtain information about medical cannabis from the internet and social media.
• Over 60 percent of patients that reported decreasing their usage of prescription drugs after using medical cannabis, also reported making fewer monthly trips to their pharmacy retailer.
• Sixty nine percent of the pharmacists surveyed believe that pharmacists should dispense medical cannabis AND counsel patients. Currently, there are only five states that require pharmacist involvement in medical cannabis dispensaries: Minnesota, Pennsylvania, New York, Connecticut and Arkansas.
Carmen Brace, who led the study in partnership with the below listed medical cannabis and pharmaceutical experts, will be attending and speaking at the upcoming American Society of Consultant Pharmacists (ASCP) Convention November 3 and 4 in Kissimmee, Florida.
• Luba Andrus, RPh, Vice President of Patient Care, MedMar Dispensaries of Illinois
• Anne Berg, PharmD, Consultant Pharmacist
• Bradley Carlson, PharmD, RPh, Director of Pharmacy, Keystone Canna Remedies and Principal, CannaRPh
• Joseph Friedman, RPh, COO of PDI Medical Dispensary of Illinois and Principal, CannaRPh
Aclara Research will continue examining results of this study in conjunction with pharmacy partners through qualitative research among both patients and adult consumers that have used cannabis to eliminate or decrease prescription drug and opioid usage. Final study results will be released in January 2018.
About Aclara
Aclara Research is a leader in the development of patient and consumer insights within the cannabis industry. The company is made up of a team of professionals who link cannabis user insights and healthcare research to solve commercial challenges. Their cannabis patient and consumer research panel offers real time access to cannabis user insights across markets, and the implications of expanding legal access of cannabis on consumer product and retailer choice. Aclara’s quantitative and qualitative research are the foundation of a customer-centric innovation strategy - market development, product innovation and improved health care outcomes. Join the conversation and connect with Aclara Research, @aclararesearch, on Facebook, Twitter and Instagram or visit Aclara Research – Home page.
News Moderator: Ron Strider 420 MAGAZINE ®
Author: Abby Penich
Contact: Contact Us – Aclara Research
Website: Aclara Research – Home page
Welcome to the 420 Press Release Forum, created as a service to our readers solely for the dissemination of cannabis and hemp industry related press releases.
It is important for us to state that all press release information published on 420Magazine.com is ONLY based on what companies and individuals (i.e. third parties not associated with 420 Magazine) publish themselves and doesn’t involve any 420 Magazine’s editorial opinion or review. 420 Magazine takes no responsibility for and disclaims the information available in form of press releases across our website.
Some press releases may be confusing at first reading without additional explanation. In such case you should contact the press release author, either the company or the individual listed as the contact on the press release itself, with any additional questions regarding the information presented on their press release.
420 Magazine has zero tolerance towards objectionable and controversial PR materials published on its website. Any PR material found to be involved into a dispute, in one way or another, and is having one or more complaints received at 420 Magazine, against it supported with enough evidences that clearly indicate, in one way or another, it is harmful, even in a remote way, to the interest of 3rd parties is ground for taking the respective press release permanently down, without prior notice.
The study also examined pharmacist perception of medical cannabis and their role in dispensing and counseling patients. Aclara and the participating pharmacists, partnered with patient advocacy groups, dispensaries and the National Community Pharmacists Association to field online surveys of each audience, resulting in more than 400 patients and 500 pharmacists nationwide.
While the full study will be released in early 2018, key preliminary findings from the research study include:
• Sixty seven percent of patients stopped using opioid medications after using medical cannabis. In addition, 29 percent of patients reported a decrease in the number of opioid medications after starting medical cannabis.
• Thirty percent of study respondents stopped using all prescription drugs after using medical cannabis.
• Eighty seven percent of pharmacists participating in the study said cannabis should be legal for medical usage. Only 15 percent of patients are talking to their pharmacist about medical cannabis. Instead, over 40 percent of patients said they obtain information about medical cannabis from the internet and social media.
• Over 60 percent of patients that reported decreasing their usage of prescription drugs after using medical cannabis, also reported making fewer monthly trips to their pharmacy retailer.
• Sixty nine percent of the pharmacists surveyed believe that pharmacists should dispense medical cannabis AND counsel patients. Currently, there are only five states that require pharmacist involvement in medical cannabis dispensaries: Minnesota, Pennsylvania, New York, Connecticut and Arkansas.
Carmen Brace, who led the study in partnership with the below listed medical cannabis and pharmaceutical experts, will be attending and speaking at the upcoming American Society of Consultant Pharmacists (ASCP) Convention November 3 and 4 in Kissimmee, Florida.
• Luba Andrus, RPh, Vice President of Patient Care, MedMar Dispensaries of Illinois
• Anne Berg, PharmD, Consultant Pharmacist
• Bradley Carlson, PharmD, RPh, Director of Pharmacy, Keystone Canna Remedies and Principal, CannaRPh
• Joseph Friedman, RPh, COO of PDI Medical Dispensary of Illinois and Principal, CannaRPh
Aclara Research will continue examining results of this study in conjunction with pharmacy partners through qualitative research among both patients and adult consumers that have used cannabis to eliminate or decrease prescription drug and opioid usage. Final study results will be released in January 2018.
About Aclara
Aclara Research is a leader in the development of patient and consumer insights within the cannabis industry. The company is made up of a team of professionals who link cannabis user insights and healthcare research to solve commercial challenges. Their cannabis patient and consumer research panel offers real time access to cannabis user insights across markets, and the implications of expanding legal access of cannabis on consumer product and retailer choice. Aclara’s quantitative and qualitative research are the foundation of a customer-centric innovation strategy - market development, product innovation and improved health care outcomes. Join the conversation and connect with Aclara Research, @aclararesearch, on Facebook, Twitter and Instagram or visit Aclara Research – Home page.
News Moderator: Ron Strider 420 MAGAZINE ®
Author: Abby Penich
Contact: Contact Us – Aclara Research
Website: Aclara Research – Home page
Welcome to the 420 Press Release Forum, created as a service to our readers solely for the dissemination of cannabis and hemp industry related press releases.
It is important for us to state that all press release information published on 420Magazine.com is ONLY based on what companies and individuals (i.e. third parties not associated with 420 Magazine) publish themselves and doesn’t involve any 420 Magazine’s editorial opinion or review. 420 Magazine takes no responsibility for and disclaims the information available in form of press releases across our website.
Some press releases may be confusing at first reading without additional explanation. In such case you should contact the press release author, either the company or the individual listed as the contact on the press release itself, with any additional questions regarding the information presented on their press release.
420 Magazine has zero tolerance towards objectionable and controversial PR materials published on its website. Any PR material found to be involved into a dispute, in one way or another, and is having one or more complaints received at 420 Magazine, against it supported with enough evidences that clearly indicate, in one way or another, it is harmful, even in a remote way, to the interest of 3rd parties is ground for taking the respective press release permanently down, without prior notice.
